Abstract
Faricimab is a bispecific antibody targeting ANG-2 and VEGF for the treatment of neovascular age-related macular degeneration (nAMD). In the TENAYA and LUCERNE trials, patients treated with individualized dosing of faricimab followed by a Treat & Extend (T&E) regime required less frequent treatments compared to aflibercept given every eight weeks (Q8W) without compromising efficacy. About 80% of patients treated with faricimab could extend their intervals beyond Q8W. However, clinical practice in nAMD is typically characterized by T&E as well as pro re nata (PRN) regimens. This research aims to assess the durability profile of faricimab vs. anti-VEGF treatments applied in such regimens.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
